Search clinical trials for: Palbociclib 125Mg Tab

Total 5516 results

Pfizer

Completed

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Breast Cancer

Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaborators

Active, not recruiting

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Pfizer

Completed

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Lymphoma, Mantle-Cell

United States
Duke-NUS Graduate Medical School
World Bank; Public Health Authority of Saudi Arabia

Completed

Understanding Food Choices in Saudi Arabia- Taxes

Diet, Healthy

Singapore
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Healthy Male Subjects

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of [14C] TAS-205 in Healthy Volunteers

Healthy Male Subjects

Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Japanese Healthy Adult Male

Japan
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Cornell University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Nudging Nutrition With Monetary Incentives Environmental Cues

Obesity | Diet | Health Behavior | Food Labeling

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Shenzhen SiBiono GeneTech Co.,Ltd

Unknown

Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

China
Takeda

Completed

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses (TAK-438_107)

Gastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)

United Kingdom
Harvard University Faculty of Medicine
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Tai Chi, Physiologic Complexity, and Healthy Aging

Healthy Aging

United States
JANSSEN Alzheimer Immunotherapy Research & Development...

Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
Chong Kun Dang Pharmaceutical

Unknown

Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients. (MONTBLANC)

Liver Transplant

Korea, Republic of
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Xuzhou Medical University

Unknown

the Effect of Tracleer on Tourniquet-associated Hypertension

Hypertension | Tourniquets | Bosentan

China
Hospital de Clinicas de Porto Alegre

Completed

Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage (MISO200)

Miscarriage in First Trimester

Brazil
Cairo University

Unknown

Combined Effect of Continuous and Interval in Addition to Tadalafil Drug on Erectile Dysfunction

Erectile Dysfunction

Egypt
University of Washington
University of Colorado, Denver; Gilead Sciences; Kenya Medical Research Institute

Completed

The Women TAF-FTC Benchmark Study

HIV Infections

Kenya
University Hospital, Basel, Switzerland

Not yet recruiting

Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) (DMT BDR)

Healthy

Switzerland
Memorial Blood Centers, Minnesota

Completed

Iron Depletion and Replacement in Blood Donors

Anemia

United States
Livzon Pharmaceutical Group Inc.
Palm Beach CRO; Keystone Bioanalytical, Inc.

Completed

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Solid Tumor Refractory to Standard Therapy

United States
University Hospital, Ghent
Ipsen

Completed

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Rectal Carcinoma

Belgium
Hanmi Pharmaceutical Company Limited

Completed

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Hypertension | Aortic Stenosis | Aortic Regurgitation | Left Ventricular Hypertrophy | LVM

Korea, Republic of
HK inno.N Corporation

Completed

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers

Hypertension

Korea, Republic of
Zhejiang Cancer Hospital
Pfizer

Recruiting

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

Breast Neoplasms

China
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Oligoastrocytoma | Oligodendroglioma

Spain
University of Texas Southwestern Medical Center
University of Pennsylvania; Pfizer

Completed

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Advanced Breast Cancer

United States
Hospital San Carlos, Madrid

Completed

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer (PALBOSPAIN)

Breast Cancer

Spain
Novartis Pharmaceuticals

Completed

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Metastatic Breast Cancer

United States
Institut Bergonié

Completed

Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)

Advanced Gastrointestinal Stromal Tumors

France
UNC Lineberger Comprehensive Cancer Center
Pfizer

Terminated

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

Metastatic Urothelial Carcinoma (UC)

United States
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Neoplasms | Lymphoma, Non-Hodgkin

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China

3

Subscribe